288 related articles for article (PubMed ID: 12138272)
1. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
Borawski J; Pawlak K; Myśliwiec M
Nephron; 2002 Aug; 91(4):671-81. PubMed ID: 12138272
[TBL] [Abstract][Full Text] [Related]
2. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.
Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2002 Apr; 17(4):637-44. PubMed ID: 11917058
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different assays for von Willebrand factor in hemodialysis patients.
Borawski J; Pawlak K; Myśliwiec M
Haemostasis; 2000; 30(6):308-15. PubMed ID: 11356999
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response.
Borawski J; Naumnik B; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2001 Jul; 16(7):1442-7. PubMed ID: 11427638
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.
Borawski J; Myśliwiec M
Clin Appl Thromb Hemost; 2002 Jan; 8(1):77-84. PubMed ID: 11991244
[TBL] [Abstract][Full Text] [Related]
6. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
10. Thyroid function, endothelium, and inflammation in hemodialyzed patients: possible relations?
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
J Ren Nutr; 2007 Jan; 17(1):30-7. PubMed ID: 17198929
[TBL] [Abstract][Full Text] [Related]
11. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
Gunnell J; Yeun JY; Depner TA; Kaysen GA
Am J Kidney Dis; 1999 Jan; 33(1):63-72. PubMed ID: 9915269
[TBL] [Abstract][Full Text] [Related]
12. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients.
Kalantar-Zadeh K; McAllister CJ; Lehn RS; Lee GH; Nissenson AR; Kopple JD
Am J Kidney Dis; 2003 Oct; 42(4):761-73. PubMed ID: 14520627
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients--the Campania Dialysis Registry.
Di Iorio B; Cirillo M; Bellizzi V; Stellato D; De Santo NG;
Int J Artif Organs; 2007 Apr; 30(4):325-33. PubMed ID: 17520570
[TBL] [Abstract][Full Text] [Related]
14. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy.
Borawski J; Naumnik B; Mysliwiec M
Clin Appl Thromb Hemost; 2002 Oct; 8(4):359-67. PubMed ID: 12516686
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
17. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
18. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
[TBL] [Abstract][Full Text] [Related]
19. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
Lazarević T; Stojimirović B; Poskurica M; Lazarević M; Mitrović N; Stolić R
Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Platelet/Lymphocyte Ratio in Hemodialysis Patients With Erythropoietin Resistance.
Taymez DG; Ucar E; Turkmen K; Ucar R; Afsar B; Gaipov A; Turk S
Ther Apher Dial; 2016 Apr; 20(2):118-21. PubMed ID: 26929254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
